On September 10, Nanjing Pharmaceutical announced its 2026 interim dividend implementation plan, marking the company's first-ever interim cash distribution. So far, over 80 A-share pharmaceutical companies have disclosed their 2026 mid-year dividend and bonus proposals, setting a new record, with more than 30% having already executed their payouts. By sector breakdown, medical devices, chemical pharmaceuticals, and traditional Chinese medicine lead the count with the highest number of dividend-paying companies.
Among the payout plans, Dong-E-E-Jiao Co.,Ltd. (SZ: 000423)tops the list with a 10-share dividend of 13.45 yuan, followed by Mindray Medical and MicroPort Endovascular in second and third place, respectively. Tibet Rhodiola, Pien Tze Huang, Livzon Group, and Sino Biological have all declared dividends of 10 yuan or more per 10 shares. Meanwhile, eight companies, including Joincare Pharmaceutical, Allist Pharmaceutical, Canwell Medical, and Haisco Pharmaceutical Group Co.,Ltd. (SZ: 002653), have offered dividends of 5 yuan or more per 10 shares. Additionally, 16 companies, such as Haisco Pharmaceutical, Dashenlin Pharmaceutical, Qizheng Tibetan Medicine, and Fangsheng Pharmaceutical, have achieved record-high dividend payouts this time.
On August 25, Dong-E-E-Jiao Co.,Ltd. announced its 2026 interim dividend plan, distributing 13.45 yuan in cash per 10 shares to all shareholders, totaling 860 million yuan. Since its first dividend in 1999, the company has cumulatively distributed cash dividends 30 times, amassing a total of over 11 billion yuan, with an average payout ratio of approximately 70%. The company stated that it consistently prioritizes shareholder returns, adhering to a policy of sustained, stable, and high-proportion cash dividends to share its high-quality development achievements with investors. Looking ahead, it will continue to balance operational planning, profitability, and shareholder interests to determine appropriate dividend timing and amounts, ensuring long-term value creation for shareholders.
A total of 15 pharmaceutical companies are making their inaugural interim cash dividend distributions, including leading players in their respective niche sectors such as Jolly Healthcare, Bright Eye Hospital, and Qianjin Pharmaceutical. Notably, Livzon Group, Jolly Healthcare, Yabao Pharmaceutical, and Nanjing Pharmaceutical have all declared cash dividends exceeding 100 million yuan, while Yabao Pharmaceutical, Foci Pharmaceutical, Tellgen Corporation, Jolly Healthcare, Dinna Bio, and Sonoscape Medical have payout ratios exceeding 50%.
In terms of total cash dividend amounts, 43 pharmaceutical companies have distributed over 100 million yuan. Mindray Medical, Yunnan Baiyao, Joincare Pharmaceutical, and WuXi AppTec have all exceeded 1 billion yuan, with an additional seven companies, including China Resources Sanjiu, Pien Tze Huang, Huadong Medicine, and Zhejiang NHU, surpassing 500 million yuan.
On August 31, Mindray Medical announced its second interim dividend for 2026, distributing 1.612 billion yuan in cash. Combined with the first interim dividend of 1.516 billion yuan paid in May, the company's cumulative cash dividends for 2026 total 3.128 billion yuan, representing 65.19% of its first-half net profit. Since its A-share listing in 2018, Mindray Medical has consistently paid dividends for eight consecutive years, with cumulative distributions exceeding 30 billion yuan. The company stated that it will continue to align its strategic development plans with shareholder returns, enhancing payout levels while supporting business expansion both domestically and internationally to create greater value for investors.
Furthermore, among the 64 pharmaceutical companies with net profits exceeding 100 million yuan and cash dividends in the first half of 2026, several stand out. Joincare Pharmaceutical has a payout ratio exceeding 100%, while Tiantan Bio, Lepu Medical, China Resources Jiangzhong, Huabang Health, and Xiaofang Pharmaceutical have all maintained payout ratios above 50%. Against a backdrop of supportive policies and regulatory encouragement in recent years, listed companies have significantly enhanced their dividend scale, frequency, and payout ratios. These tangible cash returns not only benefit shareholders but also convey positive signals, bolstering corporate investment value and reinforcing overall market stability.